BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Price:
5.59 USD
5.08%
Market Closed
Updated:
May 13, 2024
Balance Sheet
Balance Sheet Decomposition
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
| Current Assets | 496m |
| Cash & Short-Term Investments | 389m |
| Receivables | 57m |
| Other Current Assets | 50m |
| Non-Current Assets | 21m |
| PP&E | 20.9m |
| Other Non-Current Assets | 80k |
| Current Liabilities | 150m |
| Accounts Payable | 20.9m |
| Accrued Liabilities | 103.9m |
| Other Current Liabilities | 25.2m |
| Non-Current Liabilities | 822.5m |
| Long-Term Debt | 814.1m |
| Other Non-Current Liabilities | 8.4m |
Balance Sheet
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
55
|
29
|
22
|
50
|
27
|
114
|
272
|
504
|
305
|
111
|
|
| Cash Equivalents |
55
|
29
|
22
|
50
|
27
|
114
|
272
|
504
|
305
|
111
|
|
| Short-Term Investments |
18
|
23
|
33
|
64
|
78
|
22
|
28
|
3
|
120
|
278
|
|
| Total Receivables |
10
|
6
|
9
|
6
|
4
|
22
|
9
|
29
|
51
|
57
|
|
| Accounts Receivables |
10
|
6
|
9
|
6
|
4
|
22
|
9
|
29
|
51
|
57
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
2
|
1
|
0
|
2
|
0
|
7
|
16
|
28
|
29
|
|
| Other Current Assets |
6
|
4
|
3
|
5
|
4
|
6
|
8
|
13
|
14
|
21
|
|
| Total Current Assets |
89
|
64
|
67
|
125
|
114
|
164
|
324
|
566
|
517
|
496
|
|
| PP&E Net |
0
|
5
|
10
|
10
|
9
|
11
|
11
|
15
|
15
|
21
|
|
| PP&E Gross |
0
|
0
|
10
|
10
|
9
|
11
|
11
|
15
|
15
|
21
|
|
| Accumulated Depreciation |
0
|
0
|
5
|
5
|
6
|
8
|
10
|
11
|
14
|
18
|
|
| Long-Term Investments |
41
|
48
|
9
|
41
|
22
|
0
|
0
|
7
|
18
|
0
|
|
| Other Long-Term Assets |
6
|
6
|
4
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
137
N/A
|
122
-11%
|
90
-27%
|
178
+99%
|
147
-18%
|
175
+19%
|
335
+91%
|
588
+76%
|
550
-6%
|
517
-6%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
9
|
4
|
6
|
8
|
14
|
19
|
28
|
14
|
21
|
|
| Accrued Liabilities |
17
|
23
|
20
|
25
|
28
|
38
|
57
|
75
|
90
|
104
|
|
| Short-Term Debt |
30
|
28
|
28
|
29
|
29
|
30
|
30
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
7
|
5
|
9
|
0
|
0
|
0
|
25
|
|
| Other Current Liabilities |
7
|
2
|
2
|
9
|
0
|
2
|
0
|
1
|
1
|
0
|
|
| Total Current Liabilities |
57
|
62
|
54
|
75
|
70
|
92
|
106
|
104
|
106
|
150
|
|
| Long-Term Debt |
0
|
2
|
26
|
20
|
28
|
41
|
245
|
586
|
733
|
814
|
|
| Other Liabilities |
4
|
10
|
8
|
0
|
0
|
3
|
4
|
6
|
6
|
8
|
|
| Total Liabilities |
61
N/A
|
75
+22%
|
88
+18%
|
95
+7%
|
98
+3%
|
137
+40%
|
354
+158%
|
695
+96%
|
845
+22%
|
972
+15%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
|
| Retained Earnings |
468
|
511
|
566
|
632
|
732
|
841
|
1 023
|
1 208
|
1 455
|
1 681
|
|
| Additional Paid In Capital |
543
|
558
|
567
|
715
|
780
|
877
|
1 002
|
1 099
|
1 158
|
1 222
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Equity |
76
N/A
|
48
-37%
|
2
-97%
|
84
+5 138%
|
49
-41%
|
38
-22%
|
19
N/A
|
107
-454%
|
295
-175%
|
456
-55%
|
|
| Total Liabilities & Equity |
137
N/A
|
122
-11%
|
90
-27%
|
178
+99%
|
147
-18%
|
175
+19%
|
335
+91%
|
588
+76%
|
550
-6%
|
517
-6%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
72
|
73
|
74
|
98
|
110
|
154
|
177
|
184
|
188
|
206
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
